WuXi PharmaTech has struck a deal with the genomics experts at Foundation Medicine, signing on to offer the company's cancer-decoding services to drug developers in its native China.
Chinese CRO WuXi PharmaTech has bought out XenoBiotic Laboratories, a U.S. contractor focused on early-phase research, expanding its North American presence and broadening its lab-based business.
Aldea Pharmaceuticals closed a $24 million round of Series B equity financing to support the development of a drug designed to mitigate the severe--and sometimes deadly--effects of alcohol poisoning.
WuXi PharmaTech, China's largest CRO, boosted its revenue by 14.8% in the second quarter, as banner growth in its contract manufacturing business helped the company expand its global reach.
WuXi PharmaTech has increased its manufacturing capabilities in China, bolstering its fastest-growing business as it looks to expand around the globe.
More growth in its manufacturing operations helped pharma services company WuXi PharmaTech to another strong quarter.
China's WuXi PharmaTech has completed work on a biologics safety testing facility in Suzhou, adding 38,000 square feet of lab space to its sprawling presence in the area.
Chinese CRO WuXi PharmaTech notched another strong sales quarter, boosting its revenue by 11.3% thanks to escalating demand for its manufacturing services.
The rapidly expanding pharma services company WuXi PharmaTech started work on a new facility in Philadelphia for manufacturing cell therapies last month. Now it says it is ready to undertake an expansion in China that will eventually triple its manufacturing capacity.
WuXi PharmaTech, China's largest CRO, is upping its capacity in its two largest markets, wrapping up an expansion of a U.S. early-stage operation and breaking ground on an R&D campus outside of Shanghai.